Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 6/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6530263 | 0.95 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2TDP1EPHX1ENPP2 | |
| SCHEMBL27813046 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TDP1EPHX1ENPP2 | |
| SCHEMBL28241406 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TDP1EPHX1ENPP2 | |
| SCHEMBL28055861 | 0.93 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2TDP1EPHX1ENPP2 | |
| SCHEMBL2217198 | 0.89 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2TDP1ENPP2LPAR2 | |
| SCHEMBL28218153 | 0.82 | EPHX1 (0.47) | ALDH1A1SMN1; SMN2TDP1EPHX1 | |
| SCHEMBL2216626 | 0.80 | — | — | |
| SCHEMBL17097330 | 0.80 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL28324564 | 0.80 | SMN1; SMN2 (0.66) | ALDH1A1SMN1; SMN2TDP1ENPP2LPAR2 | |
| SCHEMBL6515159 | 0.77 | CYP1A2 (0.39) | ALDH1A1SMN1; SMN2TDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134696-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | Lek Pharmaceuticals D.D. (SI) | 2009-12-23 | — | — | EP | claimed |
| EP-2017267-A1 | Synthesis of statins | LEK Pharmaceuticals D.D. (SI) | 2009-01-21 | — | — | EP | claimed |
| WO-2008119810-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2008-10-09 | — | — | WO | claimed |
| EP-2134696-B1 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS (SI) | 2017-05-17 | — | — | EP | disclosed |
| CN-105358584-A | Active energy ray-polymerizable resin composition and laminate | TOYO INK SC HOLDINGS CO LTD | 2016-02-24 | — | — | CN | disclosed |
| US-8471045-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-25 | — | — | US | disclosed |
| US-20120196333-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2012-08-02 | — | — | US | disclosed |
| US-8183397-B2 | Synthesis of statins | LEK PHARMACEUTICALS D.D. (SI) | 2012-05-22 | — | — | US | disclosed |
| US-20110178295-A1 | SYNTHESIS OF STATINS | LEK PHARMACEUTICALS D.D. (SI) | 2011-07-21 | — | — | US | disclosed |
| CN-101830885-A | Method for catalytically synthesizing cyclic carbonate ester by amino acid catalyst loaded by polystyrene | UNIV SOUTH CHINA TECH | 2010-09-15 | — | — | CN | disclosed |
| EP-2134696-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | Lek Pharmaceuticals D.D. (SI) | 2009-12-23 | — | — | EP | disclosed |
| EP-2017267-A1 | Synthesis of statins | LEK Pharmaceuticals D.D. (SI) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008119810-A2 | PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2008-10-09 | — | — | WO | disclosed |
| WO-2005082892-A2 | TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-09-09 | — | — | WO | disclosed |
| CN-1112937-A | Metallocene catalyst systems, preparation and use | PHILLIPS PETROLEUM CO (US) | 1995-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178295-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | ALDH1A1 1932/4885SMN1; SMN2 4688/4885TDP1 2543/4885 |
| US-20120196333-A1 | SYNTHESIS OF STATINS | HMGCR, DHCR7, COASY | ALDH1A1 1932/4885SMN1; SMN2 4688/4885TDP1 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.